Ken Kato - Concepedia

Author

Ken Kato

National Cancer Center Hospital East ORCID

Also Known As

Akio Kuroda, Eisuke Booka, K Kato, K. Kato, KAZUHARU KATO, KEN KATO, Kato, Ken, Keitaro Kato, Ken KATO, Ken Kato

834

Publications

29.2K

Citations

H-Index

181

Concepts

All Affiliations

National Cancer Center Hospital East Aichi Cancer Center Keio University Tokyo National Hospital Shizuoka Cancer Center

About

Ken Kato is an author at National Cancer Center Hospital East specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	50	142	15.1K
2	Health Sciences	27	48	5.1K
3	Public Health	6	6	529
4	Natural Sciences	4	4	272
5	Engineering	3	3	84

Ken Kato

283

Publications

27.2K

Citations

H-Index

Page 1

	Year	Citations
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh, The Lancet Esophageal CancerGastrointestinal OncologyLeast TwoMedicineGastroenterology	2017	2.2K
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study Jong‐Mu Sun, Lin Shen, Manish A. Shah, The Lancet Chemotherapy Versus ChemotherapyOncologyEsophageal CancerGastrointestinal OncologyClinical Trials	2021	1.5K
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang, The Lancet Pembrolizumab Versus PaclitaxelGastrointestinal OncologyMedicineGastroenterologySurgery	2018	1.3K
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial Ken Kato, Byoung Chul Cho, Masanobu Takahashi, The Lancet Oncology Esophageal CancerGastrointestinal OncologyMedicinePrevious ChemotherapyNivolumab Versus Chemotherapy	2019	1.2K
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer Takashi Kojima, Manish A. Shah, Kei Muro, Journal of Clinical Oncology	2020	1.1K
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Yoon‐Koo Kang, Li‐Tzong Chen, Min‐Hee Ryu, The Lancet Oncology	2022	712
Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2 Yuko Kitagawa, Takashi Uno, Tsuneo Oyama, Esophagus	2018	585
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma Yuichiro� Doki, Jaffer A. Ajani, Ken Kato, UCL Discovery (University College London)	2022	532
Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1 Yuko Kitagawa, Takashi Uno, Tsuneo Oyama, Esophagus	2018	524
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus Manish A. Shah, Takashi Kojima, Daniel Hochhauser, JAMA Oncology	2018	511

Page 1